ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1397

Item Responses to Disease-Specific Quality of Life Questionnaires in the 18 Months Following a Flare in SLE: An Item Response Theory Analysis of a French Prospective Longitudinal Multicenter Study

Marie Corneloup1, Francois Maurier2, Denis Wahl3, Geraldine Muller4, Olivier Aumaître5, Pascal Sève6, Gilles Blaison7, Jean-Loup Pennaforte8, Thierry Martin9, Nadine Magy10, Sabine Berthier11, Laurent Arnaud12, Abderrahmane Bourredjem13, Zahir Amoura14 and Hervé Devilliers15, 1Clinical epidemiology, Clinical investigation center, INSERM CIC-EC 1432, Dijon University Hospital, 21000 Dijon, France, 2Médecine interne, Hôpitaux Privés de Metz, Metz, France, 3CHU de Nancy, Vascular Medicine Division and Regional Competence Centre For Rare Vascular And Systemic Autoimmune Diseases; and UMR_S U1116 Research Unit, Nancy, France, 4Department of Internal Medicine and Systemic Diseases, Hôpital François Mitterrand, CHU de Dijon, Dijon, France, 5Division of internal Medicine, Centre Hospitalier Universitaire, Hôpital Gabriel Montpied, Clermont–Ferrand, Clermont–Ferrand, France, 6Internal medicine, Internal medicine department, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France, 7Internal medicine departement, Colmar Hospital, Colmar, France, 8Internal Medicine, Internal medicine departement, CHU de Reims, Reims, France, 9Internal medicine and clinical immunology departement, Strasbourg University Hospital, Strasbourg, France, 10Internal Medecine, CHRU Besançon, Besancon, France, 11Department of Internal Medicine and Clinical Immunology, Dijon University Hospital, Dijon, France, 12Department of Rheumatology, Hôpitaux Universitaires de Strasbourg; INSERM UMR-S 1109, Strasbourg, France, 13Clinical investigation center, INSERM CIC-EC 1432, Dijon University Hospital, Dijon, France, 14Department of Internal Medicine, National referral center for systemic lupus erythematosus and anti-phospholipid syndrome, Pitie-Salpetriere University Hospital, Paris, France, 15Service de Médecine Interne et Maladies Systémiques, CHU de Dijon, Dijon, France

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: patient outcomes and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 22, 2018

Title: Patient Outcomes, Preferences, and Attitudes Poster I: Patient-Reported Outcomes

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: To explore, at an item-level, the effect of disease activity (DA) on disease specific health related quality of life (HRQoL) factors in systemic lupus erythematosus (SLE) patients using an item response theory (IRT) longitudinal model.

Methods: This prospective longitudinal multicenter French cohort followed SLE patients over 2 years. All patients fulfilled ACR 1997 SLE criteria. Disease specific HRQoL according to LupusQol and SLEQOL was collected every 3 months. DA according to SELENA-SLEDAI, and flare assessment according to SELENA-SLEDAI Flare Index (SFI) and organ-based revised SELENA-SLEDAI Flare Index (SFI-R) was evaluated every 6 months. Response to SLEQOL and LupusQoL items were compared between remitting and non-flaring patients, in the 18 months following a flare, using an IRT approach fitting a linear logistic model with relaxed assumptions for each dimension of the questionnaires. Parameters estimations for an item are interpreted as a difference in improvement measured by a given item according to QoL in given domain resulting in being remitting from a flare compared to patients with no flare. A parameter is considered statistically significant when different from 0 according to its 95% confidence interval.

Results: Between December 2011 and July 2015, 336 patients were included (89.9% female). Mean (SD) SELENA-SLEDAI score was 3.9(4.3). twenty-two percent were taking immunosuppressive drugs. Among patients remitting from an SFI-R muskuloskeletal flare (image 1), remission led to significant improvement in HRQoL among items of LupusQoL in the physical health and pain domains (going to the market, pain interference with the quality of sleep), and SLEQOL physical functioning, symptoms and treatment domains (walking 3 km, joint pain, fear of needles, inconvenience of clinic visits). SFI-R Cutaneous flares impacted items related to self-image issues and intimate relationships (anxiousness, attractiveness linked to skin rashes, being less interested in sex or sexual relationship). Patients HRQoL remained adversely impacted up to 18 months after a flare. LupusQoL Item “weight gain due to treatment” was negatively impacted after an ostearticular flare.

Conclusion: IRT analyses pinpoint HRQoL items most important to patients in specific situations. LupusQoL and SLEQOL items related to physical HRQoL (physical health, physical functioning and pain domains) were most influenced by muskuloskeletal or cutaneous flares.


Disclosure: M. Corneloup, None; F. Maurier, None; D. Wahl, None; G. Muller, None; O. Aumaître, None; P. Sève, AbbVie Inc., 5,Novartis, 5; G. Blaison, None; J. L. Pennaforte, None; T. Martin, None; N. Magy, None; S. Berthier, None; L. Arnaud, GSK, 2, 5,AstraZeneca, 5,Roche, 5,Janssen, 5,Eli Lilly and Co., 5,Novartis, 5,UCB, Inc., 5; A. Bourredjem, None; Z. Amoura, None; H. Devilliers, GSK, 2.

To cite this abstract in AMA style:

Corneloup M, Maurier F, Wahl D, Muller G, Aumaître O, Sève P, Blaison G, Pennaforte JL, Martin T, Magy N, Berthier S, Arnaud L, Bourredjem A, Amoura Z, Devilliers H. Item Responses to Disease-Specific Quality of Life Questionnaires in the 18 Months Following a Flare in SLE: An Item Response Theory Analysis of a French Prospective Longitudinal Multicenter Study [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/item-responses-to-disease-specific-quality-of-life-questionnaires-in-the-18-months-following-a-flare-in-sle-an-item-response-theory-analysis-of-a-french-prospective-longitudinal-multicenter-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/item-responses-to-disease-specific-quality-of-life-questionnaires-in-the-18-months-following-a-flare-in-sle-an-item-response-theory-analysis-of-a-french-prospective-longitudinal-multicenter-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology